Ipratropiumbromid Teva

Ipratropium Bromide, the active ingredient in Ipratropiumbromid Teva, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It treats chronic obstructive pulmonary disease and asthma in adult patients by relaxing airway smooth muscle and is approved in the European Union for respiratory disease management.

GNH USA supplies Ipratropiumbromid Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide is a bronchodilator used in the management of obstructive airway diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces dyspnea. - Asthma: provides add‑on bronchodilation for symptom control. - Chronic bronchitis: lessens bronchospasm and aids breathing in patients with persistent cough.

Common Side Effects: - Dry mouth - Cough or throat irritation - Headache - Dizziness - Nausea - Taste disturbance

Serious or Rare Side Effects: - Paradoxical bronchospasm - Allergic reactions such as rash or angioedema - Severe cough or chest tightness - Urinary retention (rare) - Elevated intra‑ocular pressure in susceptible individuals

Before initiating therapy, evaluate respiratory status and potential anticholinergic sensitivity. - Assess for narrow‑angle glaucoma: avoid if present. - Monitor patients with urinary retention or prostate enlargement. - Use with caution in the elderly due to increased anticholinergic burden. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium bromide may interact with other medications that affect the cholinergic system or respiratory function.

Major Interactions (Avoid): - Concurrent use with other inhaled anticholinergics (e.g., tiotropium) – risk of additive anticholinergic effects. - Combination with drugs that markedly increase intra‑ocular pressure – may exacerbate glaucoma.

Moderate Interactions (Monitor Closely):\n- Co‑administration with β2‑agonists – enhanced bronchodilation but monitor for tachycardia. - Use with antihistamines – may increase dryness of secretions. - Concomitant drugs causing urinary retention – observe for worsening symptoms.